Skip to content

Study · Case report or series · n = 2 · 2025

6 results

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.

Lee E, Burgess K

Alternative therapies in health and medicine1 Sept 2025Cited by 6 (Europe PMC)

PMID40131143 (opens in a new tab)PepBankPUB-40131143
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In 2 adults given intravenous BPC‑157, infusions had no measurable effect on the tested biomarkers of the heart.

    In plain wordsIn two adults, BPC‑157 given by drip did not change the tested heart blood markers.

    Peptide
    BPC-157
    Outcome
    No significant changeCardiac biomarkers and vital signs
    Study

    n = 2

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    10 mg, then 20 mg · intravenous · infusions on day 1 and day 2 (3-day study)As given in this study (human).

    Source sentences

    Summary
    The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels.
    2 context sentences
    Summary · context
    Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial.
    Summary · context
    On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 2, fasting blood work was repeated, vital signs were recorded, and 20 mg of BPC-157 in 250 cc of normal saline was infused over one hour.
  2. 02HumanCase report or seriesSafety outcome

    In 2 adults given intravenous BPC‑157, infusions had no measurable effect on the tested biomarkers of the liver.

    In plain wordsIn two adults, BPC‑157 given by drip did not change the tested liver blood markers.

    Peptide
    BPC-157
    Outcome
    No significant changeLiver biomarkers
    Study

    n = 2

    Outcome group
    Adverse events · Liver
    Studied dose
    10 mg, then 20 mg · intravenous · infusions on day 1 and day 2 (3-day study)As given in this study (human).

    Source sentences

    Summary
    The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels.
    2 context sentences
    Summary · context
    Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial.
    Summary · context
    On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 2, fasting blood work was repeated, vital signs were recorded, and 20 mg of BPC-157 in 250 cc of normal saline was infused over one hour.
  3. 03HumanCase report or seriesSafety outcome

    In 2 adults given intravenous BPC‑157, infusions had no measurable effect on the tested biomarkers of the kidneys.

    In plain wordsIn two adults, BPC‑157 given by drip did not change the tested kidney blood markers.

    Peptide
    BPC-157
    Outcome
    No significant changeKidney biomarkers
    Study

    n = 2

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    10 mg, then 20 mg · intravenous · infusions on day 1 and day 2 (3-day study)As given in this study (human).

    Source sentences

    Summary
    The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels.
    2 context sentences
    Summary · context
    Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial.
    Summary · context
    On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 2, fasting blood work was repeated, vital signs were recorded, and 20 mg of BPC-157 in 250 cc of normal saline was infused over one hour.
  4. 04HumanCase report or seriesSafety outcome

    In 2 adults given intravenous BPC‑157, infusions had no measurable effect on the tested biomarkers of the thyroid.

    In plain wordsIn two adults, BPC‑157 given by drip did not change the tested thyroid blood markers.

    Peptide
    BPC-157
    Outcome
    No significant changeThyroid biomarkers
    Study

    n = 2

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    10 mg, then 20 mg · intravenous · infusions on day 1 and day 2 (3-day study)As given in this study (human).

    Source sentences

    Summary
    The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels.
    2 context sentences
    Summary · context
    Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial.
    Summary · context
    On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 2, fasting blood work was repeated, vital signs were recorded, and 20 mg of BPC-157 in 250 cc of normal saline was infused over one hour.
  5. 05HumanCase report or seriesSafety outcome

    In 2 adults given intravenous BPC‑157, infusions had no measurable effect on blood glucose levels.

    In plain wordsIn two adults, BPC‑157 given by drip did not change blood sugar.

    Peptide
    BPC-157
    Outcome
    No significant changeBlood glucose
    Study

    n = 2

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    10 mg, then 20 mg · intravenous · infusions on day 1 and day 2 (3-day study)As given in this study (human).

    Source sentences

    Summary
    The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels.
    2 context sentences
    Summary · context
    Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial.
    Summary · context
    On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 2, fasting blood work was repeated, vital signs were recorded, and 20 mg of BPC-157 in 250 cc of normal saline was infused over one hour.
  6. 06HumanCase report or seriesSafety outcome

    In 2 adults given intravenous BPC‑157, the infusion was tolerated and no side effects were reported.

    In plain wordsIn two adults, BPC‑157 given by drip was tolerated and no side effects were reported. The study was too small to prove safety.

    Peptide
    BPC-157
    Outcome
    No significant changeSide effects and tolerability
    Study

    n = 2

    Outcome group
    Adverse events · Whole body
    Studied dose
    10 mg, then 20 mg · intravenous · infusions on day 1 and day 2 (3-day study)As given in this study (human).

    Source sentences

    Summary
    The BPC-157 peptide infusion was tolerated, with no side effects reported.
    2 context sentences
    Summary · context
    Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial.
    Summary · context
    On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 2, fasting blood work was repeated, vital signs were recorded, and 20 mg of BPC-157 in 250 cc of normal saline was infused over one hour.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.